AstraZeneca
Compare AstraZeneca…UK-Swedish diversified pharma. AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1) build a credible third-tier obesity franchise behind Lilly and Novo.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AstraZenecaUK-Swedish diversified pharma. AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1) build a credible third-tier obesity franchise behind Lilly and Novo.
Browse all official SEC filings including annual reports, quarterly updates, and material event disclosures.
Showing 20 of 500 filings